Metformin modifies hormone changes associated with androgen deprivation therapy for prostate cancer.
Mathew Gorman, Nawaid Usmani, Michael N Pollak, Sunita Ghosh, Arun Elangovan, Julian Kim, John Thoms, Myriam Bouchard, Michael Peacock, Ye Wang, Neil E Fleshner, Holly Campbell, Eric Vigneault, Francois Vincent, Alan So, Fabio L Cury, Harvey C Quon, Ryan G Carlson, Carole Lambert, Laurence Klotz, Kim Chi, Michael Brundage, Kerry S Courneya, Bernhard J Eigl
Endocr Oncol 6(1) e250114
摘要
摘要
Androgen deprivation therapy (ADT) is regularly used to treat locally advanced and metastatic prostate cancer (PCa) with toxicities, including metabolic syndrome (MS) and associated adverse hormonal changes. This study evaluated whether metformin mitigates changes in laboratory biomarkers associated with MS and type II diabetes mellitus (T2DM) in PCa patients receiving ADT. PRIME is a phase III double-blind, randomized controlled trial in which 166 normoglycemic patients with PCa receiving ADT were randomized to receive metformin or placebo. For this study, 47 patients from the metformin arm and 32 patients from the placebo arm underwent serum collection and analysis of the following analytes at baseline, 9, and 12 months: IGF-1, IGFBP1, IGFBP2, IGFBP3, IGFBP7, leptin, adiponectin, GDF15, insulin, C-peptide, GIP, GLP-1, and IL-6. Independent t-tests were used to determine whether significant changes in analytes were evident in patients receiving metformin vs placebo and to evaluate analyte changes from baseline for the metformin and placebo groups separately. Mean leptin values increased markedly in the placebo group and significantly less in the metformin group across all time points. Significant improvements were also observed in IGFBP1, IL-6, C-peptide, and GLP-1 with metformin compared with placebo. GDF15 and IGFBP3 significantly increased compared with baseline with ADT alone. This study demonstrates that metformin can mitigate biomarker changes induced by ADT associated with an increased risk of T2DM and MS. In addition, the attenuated increase in leptin signals a potential for improved PCa outcomes, as high leptin values have been correlated with aggressive disease and worse prognosis.
KM 提取结果
0 个 Figure · 0 个 KM 面板
其他 Figure(1,默认折叠)
这些图片未产生 KM 曲线结果,不在主页面重复展示。